BR112012011268A2 - anticorpos anti-integrina ligados a nanopartículas carregadas com agentes quimioterapêuticos - Google Patents

anticorpos anti-integrina ligados a nanopartículas carregadas com agentes quimioterapêuticos

Info

Publication number
BR112012011268A2
BR112012011268A2 BR112012011268A BR112012011268A BR112012011268A2 BR 112012011268 A2 BR112012011268 A2 BR 112012011268A2 BR 112012011268 A BR112012011268 A BR 112012011268A BR 112012011268 A BR112012011268 A BR 112012011268A BR 112012011268 A2 BR112012011268 A2 BR 112012011268A2
Authority
BR
Brazil
Prior art keywords
integrin antibodies
nanoparticle
chemotherapeutic agents
loaded
linked anti
Prior art date
Application number
BR112012011268A
Other languages
English (en)
Inventor
Rothweiler Florian
Von Briesen Hagen
Cinatl Jindrich
Kreuter Joerg
Langer Klaus
Anhorn Marion
Michaelis Martin
Wagner Sylvia
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR112012011268A2 publication Critical patent/BR112012011268A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nanotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

anticorpos anti-integrina ligados a nanopartículas carregadas com agentes quimioterapêuticos. a presente invenção refere-se a anticorpos anti-integrina que são covalentemente ligados a nanopartículas, em que essas nanopartículas foram antes carregadas com agentes quimioterapêuticos/citotóxicos. os conjugados anticorpo-agente quimioterapêutico-nanopartícula de acordo com a invenção, especialmente em que o anticorpo é mab di17e6 e o agente citotoóxico é doxorrubicina, mostram um aumento significante de toxidez de célula de tumor.
BR112012011268A 2009-11-13 2010-10-21 anticorpos anti-integrina ligados a nanopartículas carregadas com agentes quimioterapêuticos BR112012011268A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09014206 2009-11-13
PCT/EP2010/006443 WO2011057709A1 (en) 2009-11-13 2010-10-21 Anti integrin antibodies linked to nanoparticles loaded with chemotherapeutic agents

Publications (1)

Publication Number Publication Date
BR112012011268A2 true BR112012011268A2 (pt) 2019-09-24

Family

ID=43264724

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012011268A BR112012011268A2 (pt) 2009-11-13 2010-10-21 anticorpos anti-integrina ligados a nanopartículas carregadas com agentes quimioterapêuticos

Country Status (12)

Country Link
US (1) US20120263739A1 (pt)
EP (1) EP2498821A1 (pt)
JP (1) JP2013510804A (pt)
KR (1) KR20120106952A (pt)
CN (1) CN102665769A (pt)
AU (1) AU2010318323A1 (pt)
BR (1) BR112012011268A2 (pt)
CA (1) CA2780773A1 (pt)
EA (1) EA201270620A1 (pt)
IL (1) IL219523A0 (pt)
MX (1) MX2012005423A (pt)
WO (1) WO2011057709A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6320042B2 (ja) 2011-02-11 2018-05-09 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 前立腺癌治療のための抗アルファ−ｖインテグリン抗体
US9427477B2 (en) 2011-05-09 2016-08-30 Mayo Foundation For Medical Education And Research Cancer treatments
JP6035716B2 (ja) * 2011-08-26 2016-11-30 ソニー株式会社 情報処理システム及び情報処理方法
EP2861264B1 (en) 2012-07-20 2019-02-06 Canon Kabushiki Kaisha Contrast agent for photoacoustic imaging
JP6177036B2 (ja) * 2012-07-20 2017-08-09 キヤノン株式会社 光音響イメージング用造影剤
EP2903610B1 (en) 2012-10-01 2021-11-03 Mayo Foundation For Medical Education And Research Cancer treatments
CN103044437B (zh) * 2012-12-21 2015-08-26 上海交通大学 用于治疗肿瘤的两亲性缀合物纳米颗粒及制备方法、应用
WO2014143383A1 (en) 2013-03-13 2014-09-18 Agilent Technologies, Inc. Transposome tethered to a gene delivery vehicle
CN113134095A (zh) 2014-06-16 2021-07-20 梅约医学教育与研究基金会 治疗骨髓瘤
WO2015018380A2 (en) 2014-07-03 2015-02-12 Cspc Zhongqi Pharmaceutical Technology(Shijiazhuang)Co., Ltd. Therapeutic nanoparticles and the preparation methods thereof
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
CN105288639A (zh) * 2015-11-23 2016-02-03 中国药科大学 一种载阿霉素的主动靶向白蛋白纳米载体的制备及其应用
US11571469B2 (en) 2016-01-07 2023-02-07 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression
EP3413874A4 (en) 2016-02-12 2020-01-22 Mayo Foundation for Medical Education and Research HEMATOLOGICAL CANCER TREATMENTS
US11305020B2 (en) 2016-03-21 2022-04-19 Mayo Foundation For Medical Education And Research Methods for reducing toxicity of a chemotherapeutic drug
AU2017238118A1 (en) * 2016-03-21 2018-10-11 Mayo Foundation For Medical Education And Research Methods for improving the therapeutic index for a chemotherapeutic drug
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
KR102462041B1 (ko) 2016-09-01 2022-11-02 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 암 치료용 담체－ｐｄ－ｌ１ 결합제 조성물
MX2019002473A (es) 2016-09-01 2019-09-18 Mayo Found Medical Education & Res Métodos y composiciones para el direccionamiento de cánceres de células t.
US11590098B2 (en) 2016-09-06 2023-02-28 Mayo Foundation For Medical Education And Research Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
EP3509643A1 (en) 2016-09-06 2019-07-17 Mayo Foundation for Medical Education and Research Paclitaxel-albumin-binding agent compositions and methods for using and making the same
WO2018048816A1 (en) 2016-09-06 2018-03-15 Mayo Foundation For Medical Education And Research Methods of treating pd-l1 expressing cancer
MX2019003988A (es) * 2016-10-10 2019-08-14 Abraxis Bioscience Llc Formulaciones de nanoparticulas y sus metodos de fabricacion y uso.
CN109490526A (zh) * 2017-09-13 2019-03-19 南京东纳生物科技有限公司 一种抗体取向修饰的荧光微球探针的制备方法及在免疫层析中的应用
CN107857800B (zh) * 2017-11-09 2020-05-05 北京赛升药业股份有限公司 一种长效整合素抑制剂及其应用
CN108837299B (zh) * 2018-07-18 2020-08-07 武汉大学 一种智能调节血糖的微针贴片及其制备方法
CN113546087B (zh) * 2021-07-01 2022-11-25 东华大学 一种纤连蛋白包覆的单宁酸/铁配合物的载药纳米材料及其制备和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0719859T3 (da) 1994-12-20 2003-10-20 Merck Patent Gmbh Anti-alfa V-integrin monoklonalt antistof
US20070025889A1 (en) * 2005-07-28 2007-02-01 Pcbu Business Services, Inc. Reactors, reactor assemblies and production processes
DE102005062440B4 (de) * 2005-12-27 2011-02-24 Lts Lohmann Therapie-Systeme Ag Proteinbasiertes Trägersystem zur Resistenzüberwindung von Tumorzellen
US8715718B2 (en) * 2006-07-14 2014-05-06 Rutgers, The State University Of New Jersey Extracellular matrix production from nanoscale substrate
US20110177155A1 (en) * 2007-08-21 2011-07-21 Immune Disease Institute, Inc. Methods of delivery of agents to leukocytes and endothelial cells

Also Published As

Publication number Publication date
IL219523A0 (en) 2012-06-28
EA201270620A1 (ru) 2012-12-28
KR20120106952A (ko) 2012-09-27
MX2012005423A (es) 2012-06-14
CA2780773A1 (en) 2011-05-19
AU2010318323A1 (en) 2012-06-28
EP2498821A1 (en) 2012-09-19
CN102665769A (zh) 2012-09-12
JP2013510804A (ja) 2013-03-28
WO2011057709A1 (en) 2011-05-19
US20120263739A1 (en) 2012-10-18

Similar Documents

Publication Publication Date Title
BR112012011268A2 (pt) anticorpos anti-integrina ligados a nanopartículas carregadas com agentes quimioterapêuticos
BR112012024564A2 (pt) anticorpos contra csf-1r
NZ595574A (en) Anti-fcrh5 antibodies and immunoconjugates and methods of use
CY1118668T1 (el) Ανοσοσυζευγματα εναντι υποδοχεα φολικου οξεος 1 και χρησεις αυτων
NZ754811A (en) Pyrrolobenzodiazepine-antibody conjugates
MX2015001399A (es) Anticuerpos anti-etbr e inmunoconjugados.
MY173839A (en) Cd37-binding molecules and immunoconjugates thereof
AR080795A1 (es) Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6)
NZ731633A (en) Antibodies against cd73 and uses thereof
MX2013003452A (es) Conjugados de amatoxina con enlazantes mejorados.
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
MX2010005830A (es) Conjugado de anticuerpo monoclonal anti-b7h4 - farmaco y metodos de uso del mismo.
EA201270654A1 (ru) Моноклональные антитела, связывающие b7h6, и их применение
NZ710746A (en) Pyrrolobenzodiazepines and conjugates thereof
BR112013010544A2 (pt) moléculas de ligação ao egfr e imunoconjugados das mesmas
GEP20196956B (en) Anti-gcc antibody molecules and related compositions and methods
WO2015054691A3 (en) Tem8 antibodies and their use
BR112012012887A2 (pt) minicorpo e cys-diabody (cysdb) codificados por sequência de nucleótidos, respectivo uso e métodos de diagnósticos e de tratamento de câncer associado com a expressão de psma num sujeito.
NI200900022A (es) Anticuerpo especifico de prlr y usos del mismo
UA108598C2 (xx) Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери)
EA201691963A1 (ru) Производные тубулизина
NZ599045A (en) New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody
TR201903026T4 (tr) S100a4 anti̇korlari ve bunlarin terapöti̇k kullanimlari.
MX2010008570A (es) Anticuerpos alfa5-beta1 y sus usos.
EP2519542A4 (en) ANTI-CDH3 ANTIBODY AND ITS USE

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.